利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.019 秒)

    Medicament capsules for rectal application
    1.
    发明授权
    Medicament capsules for rectal application 失效
    用于直肠应用的药物胶囊

    公开(公告)号：US4402692A

    公开(公告)日：1983-09-06

    申请号：US269706

    申请日：1981-06-02

    申请人： Yasushi Takagishi ,  Yoshio Doi ,  Kanji Aita ,  Noboru Hoshi

    发明人： Yasushi Takagishi ,  Yoshio Doi ,  Kanji Aita ,  Noboru Hoshi

    IPC分类号： A61K31/48 ,  A61K9/02 ,  A61K9/48 ,  A61M7/00

    CPC分类号： A61K9/025 ,  A61K9/4816 ,  Y10S514/962

    摘要： The invention provides a novel and efficient means for the administration of a therapeutically effective ingredient by rectal application in the form of a medicament capsule encapsulating the effective ingredient. The medicament capsule according to the invention is formed of a hard capsule shell made of a mixed ester of a cellulose ether, e.g. alkyl-, hydroxyalkyl- and hydroxyalkyl alkylcelluloses, esterified with aliphatic monacyl groups and acidic succinyl groups. When the capsule is inserted into the rectum, the capsule shell is disintegrated and the rectally absorbable effective ingredient is readily and smoothly released into the rectum and absorbed to exhibit therapeutical effects as efficiently as with conventional suppositories.

    摘要翻译： 本发明提供了一种用于通过直肠施用以包封有效成分的药物胶囊的形式施用治疗有效成分的新型和有效的方法。 根据本发明的药物胶囊由纤维素醚混合酯制成的硬胶囊壳形成。 烷基，羟基烷基和羟烷基烷基纤维素，用脂族单酰基和酸性琥珀酰基酯化。 当胶囊插入直肠时，胶囊壳崩解，直肠可吸收的有效成分容易平稳地释放到直肠中并被吸收以显示与常规栓剂一样有效的治疗效果。

    Medicament capsules for rectal application
    2.
    发明授权
    Medicament capsules for rectal application 失效
    用于直肠应用的药物胶囊

    公开(公告)号：US4405597A

    公开(公告)日：1983-09-20

    申请号：US292040

    申请日：1981-08-11

    申请人： Yasushi Takagishi ,  Yoshio Doi ,  Kiichiro Ohsuga ,  Noboru Hoshi ,  Shionogi & Co., Ltd.

    发明人： Yasushi Takagishi ,  Yoshio Doi ,  Kiichiro Ohsuga ,  Noboru Hoshi ,  Shionogi & Co., Ltd.

    IPC分类号： A61K9/02 ,  A61K9/36 ,  A61K9/48

    CPC分类号： A61K9/4816 ,  A61K9/025

    摘要： The invention provides a novel means for the administration of a therapeutically effective ingredient in the form of a rectally applicable medicament capsule, in which the otherwise unavoidable extreme variation in the absorbability of the effective ingredient among the individuals rectally treated with the capsules is minimized. It has been unexpectedly found that, when the effective ingredient is contained in the capsule in the form of a liquid medicine, the osmotic pressure of the liquid content plays a very essential role in the absorption of the effective ingredient through the rectum and the variation in the absorbability of the effective ingredient among the individuals can be minimized when the osmotic pressure of the liquid content is substantially higher than the osmotic pressure of the rectal fluid with which the capsules are contacted.

    摘要翻译： 本发明提供了一种用于施用直肠可用药物胶囊形式的治疗有效成分的新方法，其中用胶囊直肠治疗的个体之间有效成分的吸收性的其他不可避免的极端变化最小化。 已经意外地发现，当液体药物形式的胶囊中含有有效成分时，液体含量的渗透压在通过直肠的有效成分的吸收中发挥非常重要的作用， 当液体含量的渗透压显着高于胶囊与其接触的直肠液的渗透压时，个体之间有效成分的吸收能力可被最小化。

    Enterosoluble hard-capsulated medicaments
    3.
    发明授权
    Enterosoluble hard-capsulated medicaments 失效
    肠溶性硬封闭药物

    公开(公告)号：US4339463A

    公开(公告)日：1982-07-13

    申请号：US169395

    申请日：1980-07-16

    申请人： Yasushi Takagishi ,  Yoshio Doi ,  Noboru Hoshi

    发明人： Yasushi Takagishi ,  Yoshio Doi ,  Noboru Hoshi

    IPC分类号： A61K9/48 ,  A61K47/00

    CPC分类号： A61K9/4858 ,  A61K9/4816 ,  A61K9/485

    摘要： The invention provides a novel means for overcoming the problem of undue and irregular delay in the exhibition of the effect of medicine when a patient is administrated with an enterosoluble hard-capsulated medicament. The unexpected discovery that the key parameter ruling the smooth transfer of an enterosoluble capsule from the stomach to the intestinal canals is the overall specific gravity of the capsule has led to the establishment of the invention which proposes an enterosoluble hard-capsulated medicament having an overall specific gravity of at least 1.05 or, preferably, at least 1.10.

    摘要翻译： 本发明提供了一种新颖的手段，克服了当患者服用肠溶性硬封闭药物时，展示药物效果的不当和不规律延误的问题。 意外的发现是，将肠溶胶囊从胃平滑转移到肠道的关键参数是胶囊的总比重导致本发明的建立，其提出了具有总体特异性的肠溶性硬封闭药物 重力至少为1.05，优选为至少1.10。

    Enterosoluble hard-capsulated medicaments
    4.
    发明授权
    Enterosoluble hard-capsulated medicaments 失效

    公开(公告)号：US4397835A

    公开(公告)日：1983-08-09

    申请号：US372791

    申请日：1982-04-28

    申请人： Yasushi Takagishi ,  Yoshio Doi ,  Noboru Hoshi

    发明人： Yasushi Takagishi ,  Yoshio Doi ,  Noboru Hoshi

    IPC分类号： A61K9/48

    CPC分类号： A61K9/4858 ,  A61K9/4816 ,  A61K9/485

    摘要： The invention provides a novel means for overcoming the problem of undue and irregular delay in the exhibition of the effect of medicine when a patient is administrated with an enterosoluble hard-capsulated medicament. The unexpected discovery that the key parameter ruling the smooth transfer of an enterosoluble capsule from the stomach to the intestinal canals is the overall specific gravity of the capsule has led to the establishment of the invention which proposes an enterosoluble hard-capsulated medicament having an overall specific gravity of at least 1.05 or, preferably, at least 1.10.

    Coating compositions for solid medicines
    5.
    发明授权
    Coating compositions for solid medicines 失效
    固体药物涂料组合物

    公开(公告)号：US3957523A

    公开(公告)日：1976-05-18

    申请号：US455533

    申请日：1974-03-28

    申请人： Shigeru Ohno ,  Noboru Hoshi ,  Fujio Sekigawa

    发明人： Shigeru Ohno ,  Noboru Hoshi ,  Fujio Sekigawa

    IPC分类号： A61K47/38 ,  A61K9/28 ,  A61K9/30 ,  A61K9/36 ,  A61K9/50 ,  C08L1/12 ,  C08L1/26

    CPC分类号： A61K9/5042 ,  A61K9/2866 ,  A61K9/5047

    摘要： When a mixture comprising 30 to 70% by weight of an enterosoluble cellulose derivative containing a monoester linkage with a polybasic acid, such as, hydroxypropyl methylcellulose phthalate, and 70 to 30% by weight of a digestive fluid-insoluble cellulose derivative, such as, ethylcellulose is used as a coating material for solid medicines, the rate of gradual release of active ingredients of the medicine in the intestinal tracts can be appropriately controlled.

    摘要翻译： 含有30〜70重量％含有与多元酸的单酯键的羟基丙基甲基纤维素邻苯二甲酸酯和70〜30重量％的消化不溶性纤维素衍生物的肠溶性纤维素衍生物的混合物， 乙基纤维素用作固体药物的涂层材料，可以适当地控制药物在肠道中的活性成分的逐渐释放的速率。

    Hard capsule
    7.
    发明申请
    Hard capsule 审中-公开
    硬胶囊

    公开(公告)号：US20050186268A1

    公开(公告)日：2005-08-25

    申请号：US11110428

    申请日：2005-04-20

    申请人： Noboru Hoshi ,  Toshio Shimamoto ,  Shigeru Sugiyama

    发明人： Noboru Hoshi ,  Toshio Shimamoto ,  Shigeru Sugiyama

    IPC分类号： A61J3/07 ,  A61K9/48 ,  A61K47/32 ,  B01J13/02 ,  B01J13/04

    CPC分类号： A61K47/32 ,  A61J3/071 ,  A61K9/4816 ,  Y10S514/962 ,  Y10T428/1352

    摘要： A method of manufacturing a hard capsule made mainly of a polymer or copolymer obtained includes polymerizing or copolymerizing at least one polymerizable vinyl monomer in the presence of polyvinyl alcohol and/or a derivative thereof. Unlike conventional hard capsules, this hard capsule can be filled with a solvent (e.g., polyethylene glycol) for a sparingly soluble drug ingredient.

    摘要翻译： 主要由聚合物或共聚物制成的硬胶囊的制造方法包括在聚乙烯醇和/或其衍生物的存在下聚合或共聚至少一种可聚合的乙烯基单体。 与常规的硬胶囊不同，该硬胶囊可以填充溶剂（例如，聚乙二醇），用于微溶药物成分。

    Preparation of readily disintegrable tablets
    10.
    发明授权
    Preparation of readily disintegrable tablets 失效
    易崩解片剂的制备

    公开(公告)号：US4017598A

    公开(公告)日：1977-04-12

    申请号：US570959

    申请日：1975-04-22

    申请人： Shigeru Ohno ,  Noboru Hoshi ,  Fujio Sekigawa

    发明人： Shigeru Ohno ,  Noboru Hoshi ,  Fujio Sekigawa

    IPC分类号： A61K9/20 ,  A61J3/10 ,  A61K47/00

    CPC分类号： A61K9/2054

    摘要： Methylcellulose with or without the addition of medically active ingredients and other additives is first granulated by a known method into granules of appropriate size and then the granules are blended with a disintegrator and compressed into tablets. The tablets obtained by the method have sufficient hardness and very short disintegration time when taken into the human body in comparison with the poor disintegrability of tablets directly shaped from powdery methylcellulose or a methylcellulose-based mixture of active ingredients. The method is useful for tableting some medicinals of poor tabletability, such as, pancreatin which require large amounts of a binder to be successfully shaped into tablets. Tablets of methylcellulose prepared in accordance with the method can find use as a non-caloried food.

    摘要翻译： 首先通过已知方法将具有或不加入医药活性成分和其它添加剂的甲基纤维素制成适当尺寸的颗粒，然后将颗粒与崩解剂混合并压制成片剂。 与由甲基纤维素粉末或甲基纤维素类的活性成分混合物直接成形的片剂的差的崩解性相比，通过该方法获得的片剂具有足够的硬度和非常短的崩解时间。 该方法可用于制备一些不良可制剂性药物，例如需要大量粘合剂成功制成片剂的胰酶。 按照该方法制备的甲基纤维素片可用作非热量食品。